FDA Commissioner Scott Gottlieb said the agency will soon make more health-related data public, including data sets compiled by FDA, adverse event reports, and letters on Risk Evaluation and Mitigation Strategies (REMS). The agency is weighing how to make public more “information that [the agency has] that [it] thinks could be relevant from a public health standpoint to providers and patients.” “What we're doing is looking broadly at different clinical information that we can make available that has public health...